Índice de contenidos
  1. OJETIVOS DOCENTES DEL MÓDULO 5
  2. 1. INTRODUCCIÓN
  3. 2. ANTICOAGULANTES ORALES ANTAGONISTAS DE LA VITAMINA K
    1. 2.1. Interacciones farmacológicas
      1. 2.1.1. Interacciones farmacodinámicas
      2. 2.1.2. Interacciones farmacocinéticas
  4. 3. ANTIAGREGANTES PLAQUETARIOS
    1. 3.1. Interacciones farmacológicas
      1. 3.1.1. Interacciones farmacodinámicas
      2. 3.1.2. interacciones farmacocinéticas
  5. 4. ENZIMAS
    1. 4.1. Enzimas fibrinolíticas
      1. 4.1.1. Interacciones farmacodinámicas
    2. 4.2. Drotrecogina alfa
      1. 4.2.1. Interacciones farmacodinámicas
  6. 5. NUEVOS ANTICOAGULANTES ORALES
    1. 5.1. Dabigatran
      1. 5.1.1. Interacciones farmacodinámicas
      2. 5.1.2. Interacciones farmacocinéticas
    2. 5.2. Rivaroxaban
      1. 5.2.1. Interacciones farmacodinámicas
      2. 5.2.2. Interacciones farmacocinéticas
  7. 6. PERSPECTIVAS DE FUTURO
  8. 7. BIBLIOGRAFÍA
Descargar curso en PDF
Módulo 5
Anexo Módulo 5
Profesor
Lourdes Girona Brumós
Pilar Lalueza Broto
Módulo 5 Acceso a Medinteract.net                                   
◄ anterior

7. BIBLIOGRAFIA

  1. National Institute for Health and Clinical Excellence. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery. 2007. http://guidance.nice.org.uk/CG46
  2. Solari P, Bosch M. ¿Cuál es la actitud frente a la trombocitopenia inducida por heparina? Med Clin (Barc). 2008;131:153-5.
  3. Budnitz DS, Shehab N, Kegler SR, Richards CL: Medication use leading to emergency department visits for adverse drug events in older adults. Ann Inter Med 2007; 147:755-765.
  4. Malone DC, Abarca J, Hansten PD, Grizzle AJ, Armstrong EP, Van Bergen RC et al. Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactions. J Am Pharm Assoc 2004; 44:142-151.
  5. Consejo General de Colegios Oficiales de Farmacéuticos. BOT Plus. Disponible en https://botplusweb.portalfarma.com (consultado el 10 de febrero de 2011)
  6. Ufer M. Comparative Pharmacokinetics of Vitami K Antagonistes. Clin Pharmacokine 2005:44: 1227-1246
  7. Fuente: Cozza KL, Armstrong SC, Oesterheld JR. Principios de interacción farmacológica para la práctica médica. Ars Medica. Barcelona 2006 (adapatdo de Wilkinson GR. 2001)
  8. Bachmann KA, Lewis JD, Fuller MA, Bonfiglio MF. Drug Interactions Handbook. Lexi-Comp,Inc. 2ª Edición. Hudson, Ohio, EEUU 2004
  9. Hansten PD, Horn JR. The Top 100 Drug Interactions. A Guide to patient Management. 2011 Edition. H&H Publications. EEUU 2011
  10. Schwarz UI. Clinical relevance of genetic polymorphims in the human CYP2C9 gene. Eur J Clin Invest 2003; 33(Suppl 2):23-30.
  11. Higashi MK, Veenstra DL, Kondo LM et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287:1690-1698.
  12. Thissen HH, Flinois JP, Beane PH. Cytochrome P4502C9 is the principal catalyst of racemic acenocumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos 2000;28:1284-90
  13. Vedovati MC, Becattini C, Agnelli G: Combined oral anticoagulants and antiplatelets: benefits and risks. Intern Emerg Med 2010; 5:281-290.
  14. Medinteract. Disponible en http://www.medinteract.net (consultado el 10 de febrero de 2011)
  15. Hyleck EM, Solarz DE. Dual Antiplatelet and Oral Anticoagulant Therapy. J Am Coll Cardiol Intv 2008; 1:62-64
  16. Sørensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jørgensen C, Madsen JK, Hansen PR, Køber L, Torp-Pedersen C, Gislason GH. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009; 374: 1967-1974.
  17. Beinema MJ, de Jong PH, Salden HJM, van Wijnen M, van der Meer J, Brouwers JR. The influence of NSAID son coumarin sensitivity in patients with CYP2C9 polymorphism after total hip replacement surgery. Mol Diag Ther 2007; 11(2): 123-128.
  18. Van Dijk KN, Plat AW, van Dijk AAC, Piersma-Wichers M, de Vries-Bots AMB, et al. Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype. Thrombosis and Haemostasis 2004; 91: 95-101
  19. Parker DL, Hoffmann TK, Tucker MA, Meier DJ. Interaction between warfarin and black tea. Annals of Pharmacotherapy 2009; 43: Online first [2 pag].
  20. Segal R, Pilote L.Warfarin interaction with Matricaria chamomilla. CMAJ: Canadian Medical Association Journal 2006; 174: 1281-1282
  21. Bungard TJ, Yakiwchuk E, Foisy M, Brocklebank C, Drug interactions involving warfarin: Practice tool and practical managemenet tips. CPJ/RPC 2011;144:21-34
  22. Morgan L. Topical drug with systemic risk. Australian Prescriber 2003 (No.2); 26: 35
  23. Thomas JL, Dunn D, Pelletier A, Franks S. Hyperprothrombinemia as a result of a possible warfarin and intravaginal miconazole interaction. Southern Medical Journal 2010;103: 1063-5
  24. Westergren T, Johansson P, Molden E.Probable warfarin-simvastatin interaction. Annals of Pharmacotherapy 41: Online first [4 pages], Jul-Aug 2007.
  25. Dixon DL, Williams VG. Interaction between gemfibrozil and warfarin: case report.and review of the literature. Pharmacotherapy 2009; 29: 744-748
  26. Mergenhagen KA, Sherman O.Elevated international normalized ratio after concurrent ingestion of cranberry sauce and warfarin. American Journal of Health-System Pharmacy 2008; 65: 2113-2116
  27. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008; 359:938-49.
  28. Kushner FG, Hand M, Smith Jr SC et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention. J Am Coll Cardiol 2009; 54:2205-41.
  29. FDA.Concomitant use of ibuprofen and aspirin: potential for attenuation of the anti-platelet effect of aspirin. Internet Document (Suppl. 3): [5 pages], 8 Sep 2006. Available from: URL: http://www.fda.gov
  30. Ficha técnica de Plavix. http://www.emea.europa.eu/humandocs/PDFs/EPAR/Plavix/H-174-PI-es.pdf (consultado el 8 de marzo de 2008)
  31. FDA. Early Communication about an Ongoing Safety Review of clopidogrel bisulfate (marketed as Plavix). 26 de enero de 2009. URL: http://www.fda.gov
  32. AEMPS. Nota informativa 2010/4 de 27 de abril de 2010: Interacción de Clopidogrel con los IBP: Actualización de la Información y recomendaciones de uso. Disponible en: http://www.aemps.es/actividad/alertas/usoHumano/seguridad/2010/NI_2010-04_clopidogrel.htm (consultado el 30 de abril de 2010)
  33. Juuelink DN, Gomes T, Ko DT, et al. A population-based estudy of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; DOI:10.1503/cmaj.082001. Disponible en http://www.cmaj.ca
  34. Ficha técnica de Efient. http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000984/WC500021971.pdf (consultado el 10 de enero de 2011)
  35. Ficha técnica de Tiklid. https://sinaem4.agemed.es/consaem (consultado el 10 de enero de 2011)
  36. Ficha técnica de Persantin. https://sinaem4.agemed.es/consaem (consultado el 10 de enero de 2011)
  37. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation (ESC Guidelines). European Heart J 2008; 29:2909-2945.
  38. White HD, Braunwald E, Murphy SA, Jacob AJ, Gotcheva N, Polonetsky L et al. Enoxaparin vs unfractionated heparin with fibrinolysis for ST- elevation myocardial infarction in elderly and young patients: results from ExTRACT-TIMI 25. European Heart J 2007; 28:1066-1071.
  39. Camporota L, Wyncoll D. Practical aspects of treatment with drotrecogin alfa (activated). Crit Care 2007; 11(suppl 5):S7.
  40. Dries D Award S, Woodward B, Wang D, Williams M. Surgical patients from the SPRESS study: prophylactic heparin in severe sepsis patients receiving Drotrecogin alfa (activated). Crit Care Med 2006; 34:A100.
  41. Marco P, Tarín F, Lucas J. Nuevos anticoagulantes orales: características de las moléculas, mecanismos de acción, farmacocinéticas y farmacodinámicas. Med Clin (Barc). 2008;131(Supl 2):66-69.
  42. Ficha técnica de Pradaxa. http://www.emea.europa.eu/humandocs/PDFs/EPAR/pradaxa/H-829-PI-es.pdf (consultado el 10 de enero de 2011)
  43. Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and Pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008; 47(1):47-59.
  44. Horn JR, Hansten PD. Dabigatran: A new oral anticoagulant. www.PharmacyTimes.com/issue/pharmacy2010/ December2010
  45. Ficha técnica de Xarelto. http://www.emea.europa.eu/humandocs/PDFs/EPAR/xarelo/H-944-PI-es.pdf (consultado el 10 de febrero de 2011)
  46. Harembergj, Whling M. Current and future prospects for anticoagulant therapy: Inhibitors of factor Xa and factor IIa. Semen Thromb Haemost. 2008;39:57